Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study

por Angarita, Fernando A., Cannell, Amanda J., Abdul Razak, Albiruni R., Dickson, Brendan C., Blackstein, Martin E.
Publicado 2016

Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial

por Van Tine, Brian A, Krarup-Hansen, Anders, Hess, Lisa M, Abdul Razak, Albiruni R, Soldatenkova, Victoria, Wright, Jennifer, Park, Se Hoon
Publicado 2022

Clinical outcomes of non‐osteogenic, non‐Ewing soft‐tissue sarcoma of bone––experience of the Toronto Sarcoma Program

por Veitch, Zachary W., Fasih, Samir, Griffin, Anthony M., Al‐Ezzi, Esmail M., Gupta, Abha A., Ferguson, Peter C., Wunder, Jay S., Abdul Razak, Albiruni R.
Publicado 2020

A phase II study of ENMD-2076 in advanced soft tissue sarcoma (STS)

por Veitch, Zachary, Zer, Alona, Loong, Herbert, Salah, Samer, Masood, Maryam, Gupta, Abha, Bradbury, Penelope A., Hogg, David, Wong, Andrew, Kandel, Rita, Charames, George S., Abdul Razak, Albiruni R.
Publicado 2019

A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events

por Janse van Rensburg, Helena J., Liu, Zhihui, Watson, Geoffrey A., Veitch, Zachary W., Shepshelovich, Daniel, Spreafico, Anna, Abdul Razak, Albiruni R., Bedard, Philippe L., Siu, Lillian L., Minasian, Lori, Hansen, Aaron R.
Publicado 2023

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index

por Day, Daphne, Guo, Christina, Kanjanapan, Yada, Tran, Ben, Spreafico, Anna, Joshua, Anthony M, Wang, Lisa, Abdul Razak, Albiruni R, Leighl, Natasha B, Hansen, Aaron R, Butler, Marcus O, Siu, Lillian L, Desai, Jayesh, Bedard, Philippe L
Publicado 2019

Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

por El-Khoueiry, Anthony B., Clarke, James, Neff, Tobias, Crossman, Tim, Ratia, Nirav, Rathi, Chetan, Noto, Paul, Tarkar, Aarti, Garrido-Laguna, Ignacio, Calvo, Emiliano, Rodón, Jordi, Tran, Ben, O’Dwyer, Peter J., Cuker, Adam, Abdul Razak, Albiruni R.
Publicado 2023

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

por Janku, Filip, Abdul Razak, Albiruni R., Chi, Ping, Heinrich, Michael C., von Mehren, Margaret, Jones, Robin L., Ganjoo, Kristen, Trent, Jonathan, Gelderblom, Hans, Somaiah, Neeta, Hu, Simin, Rosen, Oliver, Su, Ying, Ruiz-Soto, Rodrigo, Gordon, Michael, George, Suzanne
Publicado 2020

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study

por Ala‐Leppilampi, Kari, Baker, Natalie A., McKillop, Chris, Butler, Marcus O., Siu, Lillian L., Spreafico, Anna, Abdul Razak, Albiruni R., Joshua, Anthony M., Hogg, David, Bedard, Philippe L., Leighl, Natasha, Oza, Amit M., Parsons, Janet A., Hansen, Aaron R.
Publicado 2020

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

por O’Neil, Bert H., Wallmark, John M., Lorente, David, Elez, Elena, Raimbourg, Judith, Gomez-Roca, Carlos, Ejadi, Samuel, Piha-Paul, Sarina A., Stein, Mark N., Abdul Razak, Albiruni R., Dotti, Katia, Santoro, Armando, Cohen, Roger B., Gould, Marlena, Saraf, Sanatan, Stein, Karen, Han, Sae-Won
Publicado 2017

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

por de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Publicado 2019

Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma

por Gounder, Mrinal, Abdul Razak, Albiruni R, Gilligan, Adrienne M, Leong, Hoyee, Ma, Xiwen, Somaiah, Neeta, Chawla, Sant P, Martin-Broto, Javier, Grignani, Giovanni, Schuetze, Scott M, Vincenzi, Bruno, Wagner, Andrew J, Chmielowski, Bartosz, Jones, Robin L, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Riedel, Richard F, Attia, Steven
Publicado 2021

Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab

por Watson, Geoffrey Alan, Sanz-Garcia, Enrique, Zhang, Wen-Jiang, Liu, Zhihui Amy, Yang, SY Cindy, Wang, Ben, Liu, Shaofeng, Kubli, Shawn, Berman, Hal, Pfister, Thomas, Genta, Sofia, Spreafico, Anna, Hansen, Aaron R, Bedard, Philippe L, Lheureux, Stephanie, Abdul Razak, Albiruni, Cescon, Dave, Butler, Marcus O, Xu, Wei, Mak, Tak W, Siu, Lillian L, Chen, Eric
Publicado 2022

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors

por Taylor, Kirsty, Loo Yau, Helen, Chakravarthy, Ankur, Wang, Ben, Shen, Shu Yi, Ettayebi, Ilias, Ishak, Charles A, Bedard, Philippe L, Abdul Razak, Albiruni, R Hansen, Aaron, Spreafico, Anna, Cescon, Dave, Butler, Marcus O, Oza, Amit M, Lheureux, Stephanie, Stjepanovic, Neda, Van As, Brendan, Boross-Harmer, Sarah, Wang, Lisa, Pugh, Trevor J, Ohashi, Pamela S, Siu, Lillian L, De Carvalho, Daniel D
Publicado 2020

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

por Ramachandran, Indu, Lowther, Daniel E., Dryer-Minnerly, Rebecca, Wang, Ruoxi, Fayngerts, Svetlana, Nunez, Daniel, Betts, Gareth, Bath, Natalie, Tipping, Alex J., Melchiori, Luca, Navenot, Jean-Marc, Glod, John, Mackall, Crystal L., D’Angelo, Sandra P., Araujo, Dejka M., Chow, Warren A., Demetri, George D., Druta, Mihaela, Van Tine, Brian A., Grupp, Stephan A., Abdul Razak, Albiruni R., Wilky, Breelyn, Iyengar, Malini, Trivedi, Trupti, Winkle, Erin Van, Chagin, Karen, Amado, Rafael, Binder, Gwendolyn K., Basu, Samik
Publicado 2019